2023年玛丽·泰勒·摩尔视力倡议研讨会报告。
Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.
作者信息
Levine S Robert, Markel Dorene S, Myers Martin G, Barunas Ryan, Sun Jennifer K, Chang Dolly S, Maguire Maureen G, Vujosevic Stela, Fort Patrice E, Atkinson Mark, Baschiera Fabio, Gates Chris, Hunt Judy M, King George L, Kretzler Matthias, Lai Phillip, Lewis Drew, Luhmann Ulrich F O, McLeod Stephen, Oxenreiter Carol, Unsworth Shelby, Chambers Wiley, Aiello Lloyd Paul, Ehrlich Jason, German Chris L, Tadayoni Ramin, Wolf Risa M, Silva Paolo, Carlson Eric, Gott Brian, Oxenreiter Monica, Sexton Nicole, Das Arup, Gardner Thomas W
机构信息
Mary Tyler Moore Vision Initiative, Greenwich, CT, USA.
Mary Tyler Moore Vision Initiative and Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI, USA.
出版信息
Transl Vis Sci Technol. 2025 Jul 1;14(7):11. doi: 10.1167/tvst.14.7.11.
The Mary Tyler Moore Vision Initiative (MTM Vision) Diabetic Retinal Disease (DRD) Clinical Endpoints Workshop was held on November 14, 2023. More than 130 clinicians, scientists, and representatives from funding and regulatory agencies, diagnostic, therapeutic, and biotech industry and patient advocates discussed the needs for new diagnostic and therapeutic approaches to preserve and restore retinal neurovascular unit integrity in people with diabetes. MTM Vision projects, notably updating the DRD staging system and severity scale, establishing a human ocular biorepository and resource, and validating useful clinical endpoints and biomarkers to accelerate development of new drugs and improve patient care were emphasized. A public-private consortium is essential to fulfill the objectives of MTM Vision for the benefit of persons with diabetes.
玛丽·泰勒·摩尔视力倡议（MTM视力）糖尿病视网膜疾病（DRD）临床终点研讨会于2023年11月14日举行。130多名临床医生、科学家以及来自资助和监管机构、诊断、治疗和生物技术行业的代表和患者权益倡导者讨论了采用新诊断和治疗方法来保护和恢复糖尿病患者视网膜神经血管单元完整性的必要性。会上强调了MTM视力项目，特别是更新DRD分期系统和严重程度量表、建立人类眼库和资源，以及验证有用的临床终点和生物标志物以加速新药开发并改善患者护理。公私合营财团对于实现MTM视力的目标、造福糖尿病患者至关重要。
Zotero 插件